Smaller drugmakers beat Big Pharma in partnering popularity contest

Big Pharma companies aren't the most popular partners for biotechs looking to out-license products, a Boston Consulting survey found. Even top-scoring GlaxoSmithKline ($GSK) has moved down in the ranks, as smaller drugmakers like Celgene ($CELG) and Novo Nordisk ($NVO) moved up to first and second place. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.